ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

May 10, 2018

On May 8, the White House submitted a rescission package to Congress, which proposes $15 billion in cuts to 38 government programs and agencies, including to the Center for Medicare and Medicaid Innovation.

May 9, 2018

This ASCO in Action Brief is designed to help ASCO members gain a clearer understanding of the impact of state and federal right-to-try (RTT) legislation in the United States on oncology patients and practices.

May 7, 2018

On May 6, the National Institutes of Health (NIH) began national enrollment for its All of Us Research Program.  All of Us is a major component of the Precision Medicine Initiative, which aims to gather data from more than one million people living in the United States to speed up health research breakthroughs and create individualized prevention, treatment, and care for all patients. 

May 4, 2018

On May 4, 2018, the Food and Drug Administration approved dabrafenib (TAFINLAR®, Novartis Pharmaceuticals Corp.) and trametinib (MEKINIST®, Novartis Pharmaceuticals Corp.) in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

May 3, 2018

On May 1, 2018, the Food and Drug Administration approved tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

May 3, 2018

ASCO’s Policy Issue Briefs provide succinct overviews and relevant data on major policy issues impacting patients with cancer and the physicians who care for them. These briefs are designed to be especially helpful for journalists, offering background information on key issues across health policy today. 

May 2, 2018

Register now to join research colleagues from across the U.S. at the ASCO Research Community Forum Annual Meeting. The meeting offers physician researchers and research staff, from a variety of types of research programs, a unique platform to collaborate and develop solutions to common challenges with conducting oncology clinical trials.

May 1, 2018

The American Society of Clinical Oncology (ASCO) announced today that Trevor Royce, MS, MD, MPH, and Sheetal Kircher, MD, have been selected for the ASCO Health Policy Fellowship Program. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge-base, skills, and experience necessary to shape regulatory and legislative policies that directly affect the practice environment and impact patients with cancer and their care teams. 

April 30, 2018

On April 30, 2018, the Food and Drug Administration granted regular approval to dabrafenib (TAFINLAR®, Novartis Pharmaceuticals Corp.) and trametinib (MEKINIST®, Novartis Pharmaceuticals Corp.) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

April 27, 2018

ASCO submitted testimony calling on Congress to increase funding for the National Institutes of Health (NIH) and National Cancer Institute (NCI) in Fiscal Year 2019.

April 26, 2018

ASCO joined nearly 50 medical organizations in urging the Centers for Medicare & Medicaid Services (CMS) to reduce the quality performance period under the 2018 Merit-based Incentive Payment System (MIPS) to 90 days instead of a full calendar year.

April 24, 2018

An analysis published today in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice (JOP), suggests that including cancer drug costs in bundled payments under Medicare risks destabilizing the cancer care delivery environment. According to the report, Medicare reimbursement would vary widely in such a model depending on the mix of patient conditions practices treat, rather than the quality of care they provide—with reimbursement to practices that see a large volume of complex patients declining significantly from current levels.

April 23, 2018

Last week, members of PracticeNET came together for their biannual networking meeting, where participants reviewed benchmarking data and preliminary results from the 2018 Survey of Oncology Practice Operations, and received updates on new initiatives, including ASCO’s new practice website, ASCO Practice Central.

April 20, 2018

A new study in the Journal of Oncology Practice offers insights on improving cessation rates for people living with cancer who smoke. The results indicate that that talking with patients about the harms of continued smoking with a cancer diagnosis could be beneficial, particularly for those who perceive smoking to be less risky to their health.

April 20, 2018

A new editorial in the Journal of Oncology Practice provides an overview of existing initiatives designed to attract and support medical students and oncology trainees who are about to enter the workforce.